Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
NTRB
Strong SellHot AirNutriband Inc. · Healthcare · United States · $54M · Avg Vol: $233K/d
19
StockRankGet insider-trade alerts
Q
22
V
21
M
59
P/E (TTM)
—
ROE
-145.7%
D/E
0.0x
Dividend %
—
COMPANY DESCRIPTION
Nutriband Inc. develops a portfolio of transdermal pharmaceutical products in the United States. Its lead product is AVERSA Fentanyl, an abuse deterrent fentanyl patch for the treatment of chronic pain. The company also develops AVERSA buprenorphine and AVERSA methylphenidate.
FINANCIAL SUMMARY (USD)
| Year | 2023 | 2024 | 2025 | 2026 | CAGR | TTM |
|---|---|---|---|---|---|---|
| Revenue | 2.1M | 2.1M | 2.1M | 2.0M | -0.7% | 1.8M |
| EPS | -0.53 | -0.69 | -0.99 | -2.58 | — | -2.56 |
| Shares | 7.8M | 8.9M | 11.1M | 12.2M | +55.2% | 12.2M |
| Debt | 0.2M | 0.2M | 0.2M | 0.2M | 9.7% | 0.2M |
| Equity | 8.6M | 6.4M | 6.4M | 6.7M | -8.0% | — |
| Op CF | -3.0M | -3.5M | -4.6M | -5.1M | — | -4.4M |
| Inv CF | -79.3K | -51.8K | -92.0K | -5.3K | — | — |
| Fin CF | 0.2M | 2.1M | 8.5M | 5.4M | — | — |
Loading 1Y...
PRICE (1Y)+108.9%
SMA 50SMA 200
Close
$6.08
RSI (14)
74.4
52W High
$8.63
From 52W High
0.7%
SCORE BREAKDOWN
Quality
22
ROIC
-119.2%5.3
ROE
-145.7%6.0
GP/Assets
6.8%20.8
Op. Margin
-289.4%12.3
FCF/Assets
-68.1%4.5
Piotroski
431.0
Int. Cover
-50.0x5.9
D/E Ratio
0.04x73.7
Current Ratio
5.26x73.5
Value
21
P/E (TTM)
—N/A
EV/EBITDA
-8.6x25.0
P/FCF
—N/A
P/B
12.1x9.7
P/S
40.3x10.6
Div Yield
—N/A
Momentum
59
52W High %
70%52.2
RS 6M
42%90.0
SMA 50/200
0.92x35.3
EPS Rev 4W
—N/A
EPS Rev 12W
—N/A
EPS Improve
+91%71.5
Q Growth
—N/A
FUNDAMENTALS
Market Cap
$54M
P/E (Forward)
-26.0x
Gross Margin
28.4%
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of NTRB are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| NTRB | Nutriband Inc.(you) | $54M | 19 | Strong Sell |
| PMVP | PMV Pharmaceuticals, Inc. | $65M | 19 | Strong Sell |
| HYPD | Hyperion DeFi, Inc. | $51M | 16 | Strong Sell |
| ELOX | Eloxx Pharmaceuticals, Inc. | $52M | 15 | Strong Sell |
| INKT | MiNK Therapeutics, Inc. | $58M | 15 | Strong Sell |
| 4875.T | MediciNova, Inc. | $70M | 18 | Strong Sell |
| IMA | ImageneBio, Inc. | $61M | 15 | Strong Sell |
| NRXS | NeurAxis, Inc. | $75M | 18 | Strong Sell |
| SER | Serina Therapeutics, Inc. | $62M | 14 | Strong Sell |
| LONA | LeonaBio, Inc. | $75M | 18 | Strong Sell |
Peer medians: ROE -30.2% · P/E 27.0x · Gross margin 58.3%